<DOC>
	<DOCNO>NCT00789958</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine gemcitabine , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving one drug ( combination chemotherapy ) together radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give capecitabine together gemcitabine follow capecitabine radiation therapy work treat patient cholangiocarcinoma gallbladder bile duct .</brief_summary>
	<brief_title>S0809 : Capecitabine , Gemcitabine , RT Patients w/Cholangiocarcinoma Gallbladder Bile Duct</brief_title>
	<detailed_description>OBJECTIVES : - To estimate stratum-specific ( R0 R1 ) overall 2-year survival probability patient extrahepatic cholangiocarcinoma treat adjuvant chemotherapy comprise capecitabine gemcitabine hydrochloride , follow capecitabine radiotherapy . ( R0 stratum close 12-15-11 ) - To estimate 2-year stratum-specific overall disease-free survival local disease-free survival patient treat regimen . - To assess frequency severity toxicity patient treated regimen . OUTLINE : This multicenter study . Patients stratify accord margin resection ( negative [ R0 ] v microscopically positive [ R1 ] ) . ( R0 stratum close 12-15-11 ) - Adjuvant chemotherapy : Patients receive oral capecitabine every 12 hour day 1-14 gemcitabine hydrochloride IV 30 minute day 1 8 . Treatment repeat every 21 day 4 course absence disease progression unacceptable toxicity . - Chemoradiotherapy : Beginning week 13 , patient receive oral capecitabine every 12 hour day 1-7 . Patients also undergo concurrent three-dimensional intensity-modulated radiotherapy day 1-5 . Treatment repeats weekly 5-6 week absence disease progression unacceptable toxicity . After completion study therapy patient follow periodically 5 year .</detailed_description>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histopathologically confirm extrahepatic cholangiocarcinoma gallbladder bile duct , meet least 1 follow criterion : Pathological T24 disease Pathological N1 disease Positive margin ( T N ) Must undergone potentially curative radical resection negative ( R0 ) microscopically positive ( R1 ) margin within past 56 day recover ( R0 stratum close 121511 ) No distant metastatic disease indicate CT scan MRI chest , abdomen , pelvis within past 42 day Positive resect regional lymph node allow No ampullary cancer PATIENT CHARACTERISTICS : Zubrod performance status 01 ANC &gt; 1,500/μL Platelet count &gt; 100,000/μL Serum creatinine &lt; 1.5 mg/dL Total bilirubin &lt; 1.5 time upper limit normal ( ULN ) SGOT SGPT &lt; 2.5 time ULN Not pregnant nursing Fertile patient must use effective contraception Able swallow enteral medication requirement feed tube No intractable nausea vomit No gastrointestinal ( GI ) tract disease result inability take oral medication , malabsorption syndrome , requirement IV alimentation , prior surgical procedure affect absorption . uncontrolled inflammatory GI disease ( e.g. , Crohn disease , ulcerative colitis ) No uncontrolled intercurrent illness include limited following : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Myocardial infarction cerebrovascular accident within past 3 month Uncontrolled diarrhea Psychiatric illness social situation would limit compliance study requirement No prior malignancy except adequately treat basal cell ( squamous cell ) skin cancer , situ cervical cancer , cancer patient diseasefree 5 year PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior chemotherapy radiotherapy disease No prior upper abdominal radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cholangiocarcinoma extrahepatic bile duct</keyword>
	<keyword>cholangiocarcinoma gallbladder</keyword>
	<keyword>localize extrahepatic bile duct cancer</keyword>
	<keyword>localize gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>metastatic extrahepatic bile duct cancer</keyword>
	<keyword>metastatic gallbladder cancer</keyword>
</DOC>